Studies have shown that patients with dMMR, high TMB, EBV+, and PD-L1 positivity are more likely to respond better to PD-L1 inhibitors [168], but there is still a lack of drugs that can treat most patients with cancer, and immune checkpoint inhibitors have shown efficacy in only about 10% of patients with gastric cancer [105]. The gene discussed is CD274; the disease is gastric cancer.